Azitra Q3 2025 Earnings Report

Azitra EPS Results

• Actual EPS: -$0.67
• Consensus EPS: -$0.79
• Beat/Miss: Beat by +$0.12
• One Year Ago EPS: N/A

Azitra Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Azitra Announcement Details

• Quarter: Q3 2025
• Date: 11/12/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 12, 2025
• Conference Call Time: 7:00AM ET

Azitra (NYSEAMERICAN:AZTR) Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance. By delivering live commensal organisms directly to affected skin regions, Azitra seeks to restore healthy barrier function and reduce inflammation without relying on conventional small-molecule or biologic drug approaches.

Founded in 2018, Azitra is traded on the NYSE American under the symbol AZTR. Its research and development operations combine microbiology, formulation science and translational dermatology, and the company’s clinical trials are conducted primarily in North America. Azitra has pursued collaborations with academic and medical centers to support its pipeline advancement.

Azitra’s leadership team brings together expertise in microbiome research, dermatology and pharmaceutical development, guiding the company toward regulatory milestones and strategic partnerships. With a mission to harness the therapeutic potential of the skin microbiome, Azitra aims to offer novel, targeted treatments for patients with chronic skin diseases.